Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. has announced the submission of a Type C meeting request to the FDA to discuss a registration-enabling trial for pelareorep in treating HR+/HER2- metastatic breast cancer, with overall survival results expected in the second half of 2024. The trial will build on promising data from previous studies, aiming to enhance clinical outcomes and further the development of pelareorep. The company looks forward to collaborating with the FDA to finalize the trial design, marking a significant step towards introducing this innovative therapy to patients.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
